Pradaxa Maker Fined Nearly $1M for Losing Court Documents
Boehringer Ingelheim Pharmaceuticals must pay a nearly $1 million fine after a judge ruled it failed to preserve files crucial to the company’s upcoming litigation against its blood thinner Pradaxa....
View ArticleDiet Soda Sales Fizzle Out Amid Diabetes, Obesity Concerns
Americans are losing their taste for diet sodas – and that’s a good thing. A recent report by Wells Fargo, citing Nielsen scanner data, shows sales of zero- and low-calorie soft drinks fell nearly 7...
View ArticleGSK Will Quit Paying Doctors to Push Its Drugs
GlaxoSmithKline will stop paying and providing perks for doctors and industry professionals to promote their drugs or base the compensation of sales representative on the amount of prescriptions...
View ArticleStryker Settles First Set of Hip Lawsuits for Undisclosed Amount
Stryker Corp. settled the first four cases in what could be a wave of settlements involving its recalled Rejuvenate and ABG II hip implants. According to news reports, lawyers for the four plaintiffs...
View ArticleEli Lilly Faces Financial Hurdles over Loss of Cymbalta Patent
Eli Lilly is banking that new drugs will counter the massive drop in profits from losing exclusivity of its top-selling antidepressant Cymbalta. The FDA already approved six less costly versions of the...
View ArticleTakeda Scraps Development of Experimental Type 2 Diabetes Drug
Japanese pharmaceutical company Takeda is dropping plans to develop diabetes drug fasiglifam (TAK-875) because clinical trials showed participants developed dangerous side effects, including possible...
View ArticleActive Lifestyles Increase Knee Replacement Surgeries in Younger Adults
The number of total knee replacement surgeries doubled in the U.S during the last decade, a recent study shows. A 2013 report published in the Journal of Bone and Joint Surgery showed that more...
View ArticleJohnson & Johnson Shifting from Devices to Drugs in 2014
Drugmaker Johnson & Johnson is shifting its focus from medical devices and diagnostic equipment to pharmaceuticals, a strategy that will give Merck and Pfizer a good amount of competition this...
View ArticleFDA Approves Farxiga to Treat Type 2 Diabetes
The U.S. Food and Drug Administration in early January approved a new pill from Bristol-Meyers Squibb Co. and AstraZeneca to treat Type 2 diabetes after previously rejecting the drug. FDA officials...
View ArticlePradaxa Back Under Review by the FDA
FDA officials will again review Pradaxa, one of the best-selling blood thinners on the market that is also linked to accidental, uncontrollable bleeding. The review by the U.S. Food and Drug...
View Article
